治疗弥漫性大B细胞淋巴瘤的抗体药物偶联物:维泊珠单抗  

An antibody-drug conjugate in treating diffuse large B-cell lymphoma: polatuzumab vedotin

作　　者：杨君义 接贵涛 YANG Jun-yi;JIE Gui-tao(Department of Pharmacy,Central Hospital of Linyi City,Linyi SHANDONG 276400,China;Department of Hematology,Central Hospital of Linyi City,Linyi SHANDONG 276400,China)

机构地区：[1]临沂市中心医院药学部,山东临沂276400 [2]临沂市中心医院血液科,山东临沂276400

出　　处：《中国新药与临床杂志》2020年第6期346-348,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：维泊珠单抗为一种抗体药物偶联物,可选择性作用于B细胞受体中的CD79b,释放出小分子细胞毒药物单甲基奥瑞他汀(MMAE)。MMAE具有抗有丝分裂的作用,能作用于微管蛋白从而抑制肿瘤生长。维泊珠单抗由基因泰克制药公司研制,于2019年6月获美国食品和药物管理局加速批准,与苯达莫司汀和利妥昔单抗联合治疗至少接受过2次前期治疗的复发难治性弥漫大B细胞淋巴瘤成人患者。维泊珠单抗常见不良反应有中性粒细胞减少、血小板减少、贫血、周围神经病变、疲劳及腹泻等。Polatuzumab vedotin is an antibody-drug conjugate that selectively acts on CD79 b in B-cell receptors and releases the small molecule cytotoxic drug monomethyl auristatin E(MMAE).MMAE has anti-mitotic effect and it can act on tublin to inhibit tumor growth.Polatuzumab vedotin was developed by Genentech,Inc.and was approved by the U.S.FDA in June,2019.It was approved to combine with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least two prior therapies.The common adverse reactions of polatuzumab vedotin included neutropenia,thrombocytopenia,anemia,peripheral neuropathy,fatigue,diarrhea and so on.

关 键 词：维泊珠单抗 淋巴瘤 大B细胞 弥漫性 CD79b抗原 抗体药物偶联物 

分 类 号：R733.4[医药卫生—肿瘤] R979.1[医药卫生—临床医学]